InhaTarget Therapeutics is founded in 2018, operates from its headquarter in Boulevard du Triomphe Ixelles, Brussels Region 1050, BE. The company operates in the Manufacturing, Pharmaceuticals sector.
InhaTarget Therapeutics specializes in Pulmonary drug delivery, Dry powders for inhalation (DPI), Particle engineering techniques, High-pressure homogenization, Spray-drying, GMP production, In vitro evaluation, Preclinical studies, In vivo evaluation, Clinical outcomes, and offers services including Innovative and targeted dry powders for inhalation (DPI), Proprietary products for respiratory diseases, and Custom developed DPIs for inhalation.